Sodha Neel R, Sellke Frank W
a Division of Cardiac Surgery, Alpert Medical School , Brown University , Providence , RI , USA.
Expert Rev Cardiovasc Ther. 2016 Aug;14(8):889-93. doi: 10.1080/14779072.2016.1203253. Epub 2016 Jun 30.
The use of novel oral anticoagulants such as dabigatran has been increasing over the last five years. Indicated for use in the prevention of thromboembolic complications from non-valvular atrial fibrillation and for the treatment and prevention of venous thromboembolic disease, dabigatran is increasingly encountered clinically. Lack of an efficacious reversal agent has been a challenge for increased clinical 10 adoption, and for management of patients with bleeding complications while taking dabigatran, or those requiring urgent procedures while taking dabigatran. Idarucizumab, a monoclonal antibody fragment, has recently been approved for use to reverse anticoagulation with dabigatran in patients with serious bleeding.
Herein we discuss the development and early clinical data evaluating the use of idarucizumab for dabigatran reversal. Expert commentary: Idarucizumab has been shown to be an efficacious reversal agent for patients receiving dabigatran. The drug provides a novel and clinically useful agent for patients with significant bleeding while receiving dabigatran, or those needing urgent invasive procedures.
在过去五年中，达比加群等新型口服抗凝剂的使用一直在增加。达比加群被用于预防非瓣膜性心房颤动的血栓栓塞并发症以及治疗和预防静脉血栓栓塞性疾病，在临床上越来越常见。缺乏有效的逆转剂一直是其临床应用增加的一个挑战，对于服用达比加群时出现出血并发症的患者或服用达比加群时需要紧急手术的患者的管理也是如此。艾达赛珠单抗，一种单克隆抗体片段，最近已被批准用于严重出血患者中逆转达比加群的抗凝作用。
在此我们讨论评估艾达赛珠单抗用于逆转达比加群抗凝作用的研发情况和早期临床数据。专家评论：艾达赛珠单抗已被证明是接受达比加群治疗患者的一种有效逆转剂。该药物为服用达比加群时出现严重出血的患者或需要紧急侵入性手术的患者提供了一种新型且具有临床实用性的药物。
